

# Allianz Life World Healthscience Fund

### May 2025

#### **Investment Objective**

The Allianz Life World Healthscience Fund (the "Fund") seeks to maximise total return by investing globally in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.

| Terms                                   | YTD    | 1 month | 3 months | 6 months | 1 year  | Since Inception<br>(Annualised) |
|---|--------|---------|----------|----------|---------|---------------------------------|
| Allianz Life World Healthscience Fund   | -5.54% | -4.69%  | -12.42%  | -10.12%  | -13.40% | -11.73%                         |
| Benchmark: MSCI World Healthcare Index* | -0.64% | -3.63%  | -7.65%   | -6.69%   | -5.19%  | -3.49%                          |
| Target Fund (USD)                       | -1.26% | -3.11%  | -9.17%   | -7.09%   | -5.78%  | -4.67%                          |

RM appreciated 11.96% (since inception)

\*Source: Bloomberg and https://www.blackrock.com/uk

The above performance is calculated in Ringgit Malaysia on a NAV-to-NAV basis. It is strictly the performance of the investment fund and not the returns earned on the actual premiums paid of the investment-linked product. Past performance is not an indication of future performance.

Bid price

#### **Performance Since Inception**



#### Portfolio Composition by Asset Type

Target Fund



Cash & Deposit 3.2%

| Facts on Target Fund |  | Key Fund Facts (at 31 Mc          | Key Fund Facts (at 31 May 2025)        |  |  |
|----------------------|--|-----------------------------------|--|--|--|
| Name                 | BGF World Healthscience Fund             | Fund Size                         | RM39.718 million                       |  |  |
| ISIN                 | LU0122379950                             | Risk Profile                      | Moderate to high                       |  |  |
| Туре                 | Undertaking for Collective Investment in | Launch Date                       | 21 February 2024                       |  |  |
|                      | Transferable Securities                  | Fund Currency                     | Ringgit Malaysia                       |  |  |
| Fund Manager         | BlackRock (Luxembourg) S.A.              | Investment Manager                | Allianz Life Insurance Malaysia Berhad |  |  |
| Fund Currency        | USD                                      | Pricing Frequency                 | Daily                                  |  |  |
|                      |  | Price per Unit - Bid <sup>1</sup> | RM0.853                                |  |  |
|                      |  | Management Fee                    | 1.50% p.a                              |  |  |
|                      |  |                                   |  |  |  |

#### 50% p.a Include but not limited to government tax, auditor Other Charges<sup>2</sup> fee, custodian fee & transaction charges

6.87%

#### Portfolio Analysis of Target Fund

Source: https://www.blackrock.com/uk Geographic Breakdown (%)

| UNITED STATES               |       | 74.02 |
|-----------------------------|-------|-------|
| SWITZERLAND                 | 8.72  |       |
| UNITED KINGDOM              | 4.31  |       |
| FRANCE                      | 3.24  |       |
| DENMARK                     | 2.41  |       |
| CASH AND/OR DERIVATIVES     | 1.94  |       |
| JAPAN                       | 1.65  |       |
| GERMANY                     | 1.07  |       |
| BELGIUM                     | 1.06  |       |
| AUSTRALIA                   | 0.99  |       |
| OTHER                       | 0.60  |       |
| or Breakdown (%)            |       |       |
| PHARMACEUTICALS             |       | 34.03 |
| HEALTH CARE EQUIP. & SUPPLY | 25.85 |       |

Top 10 Holdings (%) ABBVIE INC

ELI LILLY

| ABBVIE INC             | 5.83%  |
|------------------------|--------|
| JOHNSON & JOHNSON      | 5.13%  |
| ABBOTT LABORATORIES    | 5.08%  |
| BOSTON SCIENTIFIC CORP | 4.90%  |
| ASTRAZENECA PLC        | 4.30%  |
| UNITEDHEALTH GROUP INC | 3.87%  |
| ROCHE HOLDING PAR AG   | 3.34%  |
| AMGEN INC              | 2.64%  |
| MEDTRONIC PLC          | 2.52%  |
| Total of Portfolio     | 44.48% |

### Secto

- BIOTECHNOLOGY
- HEALTH CARE PROVIDERS & SERVICES LIFE SCIENCES TOOLS & SERVICES
  - CASH AND/OR DERIVATIVES 1.94
    - CAPITAL MARKETS | 0.13
    - HEALTH CARE TECHNOLOGY | 0.12
- 15.89 14.41 7.64



## Allianz Life World Healthscience Fund

May 2025

1. The price per unit of the Fund is the total market value of assets in the Fund divided by the total number of units of the Fund. To ensure fair treatment to all unit holders, transaction costs of acquiring and disposing of assets of the Fund are recouped by making a dilution or transaction cost adjustment to the NAV per unit of the Fund. Allianz Life Insurance Malaysia Berhad retains the right to suspend issuance or redemption of units of the Fund under exceptional circumstances, e.g. temporary closure of any stock exchange, as disclosed in the fund brochure. 2. Expenses directly related to and necessary in operating the Fund.

Disclaimer:

The Fund is a unit-linked fund offered by Allianz Life Insurance Malaysia Berhad ("Allianz"). This fact sheet is prepared by Allianz and is for information only. The fund fact sheet of the Target Fund will be available at <htps://www.blackrock.com/uk>. The performance of the Fund is not guaranteed and the value of the units and the income derived there from may increase or decrease. Past returns and any forecast is not necessarily a guide to future performance. Allianz does not warrant or make any representations that the Fund will guarantee profits, or not result in losses or the correctness, accuracy, reliability, or otherwise of this fact sheet. Before deciding to invest in the Fund, you should carefully consider your investment objectives, level of experience, and risk appetite. Allianz disclaims any and all liabilities against loss, damages, etc whether direct, indirect or consequential as a result of your reliance on this fact sheet. You should be aware of all the risks associated with fluctuations in a unit-linked fund and are advised to seek the advice of your financial consultant before making any investment.

For MSCI's disclaimer, please refer to https://www.msci.com/notice-and-disclaimer-for-reporting-licenses.